Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating anxiety-related disorders

A technology for related diseases and anxiety disorders, applied in drug combination, drug delivery, pharmaceutical formulation, etc., can solve problems such as adverse side effects of psychopharmacological drugs

Pending Publication Date: 2021-11-26
HOFFMAN TECH LLC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] However, psychopharmacological drugs have serious adverse side effects, including suicidal ideation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] During the course of the study described below, patients with OCD or SAD were observed to have improved anxiety-related symptoms.

[0077] Study Title: Double-blind, randomized, placebo-controlled, dose-ranging study of the use of L1-79 in the treatment of autism

[0078] Study design: blinded, randomized, 4-group, 4-week treatment period. Treatment groups consisted of α-methyl-DL-tyrosine (ie L1-79) or placebo three times daily (tid) at doses of 100 mg or 200 mg.

[0079] Sample size: N=30; randomized and divided into 4 groups with 10 open marks:

[0080] Group 1 (n=10) 100mg L1-79 (1×100mg capsule + 1 placebo) TID

[0081] Group 2 (n=5) 100mg L1-79 (1×100mg capsule + 1 placebo) TID

[0082] Group 3 (n=10) 200mg L1-79 (2 x 100mg capsules) TID

[0083] Group 4 (n-5) 200mg L1-79 (2 x 100mg capsules) TID

[0084] Group 5 (n=10) placebo (3 placebo) TID

[0085] Study Population: Male subjects between the ages of 13 and 21 diagnosed with autism who met the inclusion c...

Embodiment 2

[0119] Example 2 Case Study Showing Reduction of Obsessions and Compulsive Behaviors

[0120] ASD patients (Subject JW) had a history of obsessive thoughts and compulsive behaviors that negatively affected their functioning. Due to the intensity of the obsessions, obsessions make it difficult for JW to have meaningful conversations with others or to understand his or her surroundings. When taking L1-79 (100 to 200 mg three times a day), obsessive thoughts were significantly reduced to the extent that JW was able to have meaningful conversations with others, understand concepts, and make observations that would otherwise not have occurred due to the intensity of the obsessive thoughts occur. Rigid and stubborn thinking is also alleviated. Compulsions / routines can be delayed or skipped because something else of interest replaces the need to engage in the compulsion or cling to the obsession.

[0121] This disclosure also relates to the following:

[0122] Aspect 1. A method ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides methods, compositions, and kits for treating anxiety -related disorders, including OCD and SAD, and for reducing anxiety, obsessive behavior, or compulsive behavior in subjects in need thereof.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 800,016, filed February 1, 2019, the entire contents of which are incorporated herein by reference. technical field [0003] The present invention generally relates to methods for use in the treatment of anxiety-related disorders, including obsessive-compulsive disorder (OCD) and social anxiety disorder (Social Anxiety Disorder, SAD) in patients in need thereof and for use in patients in need thereof. Compositions, kits and methods for reducing anxiety, obsessive behaviors or compulsions in a patient. Background technique [0004] Mental health disorders are typically diagnosed using the criteria set forth in the American Psychiatric Association's Diagnostic and Statistical Manual (DSM). The fourth edition of the DSM (DSM-IV) grouped OCD together with generalized anxiety disorder (GAD), panic disorder, post-traumatic stress d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P25/22A61K9/20A61K31/192A61K31/195A61K31/197A61K31/4045A61K38/095
CPCA61K31/4045A61K31/197A61P25/22A61K31/198A61K38/095A61K45/06A61K9/48A61K2300/00A61K9/0053
Inventor 史蒂文·霍夫曼约翰·罗思曼
Owner HOFFMAN TECH LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com